Stockwatch

Date	Sym	Type	Headline
2024-03-27 14:00	UU:HOTH	News Release200	Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds
2024-03-27 08:27	UU:HOTH	News Release200	Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity Treatment
2024-03-19 08:21	UU:HOTH	News Release200	Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ
2024-02-29 08:38	UU:HOTH	News Release200	Hoth Therapeutics Retains Venable LLP to Expand Its Patent Portfolio
2024-02-26 08:11	UU:HOTH	News Release200	Hoth Therapeutics Engages Altasciences to Perform Key Study for HT-KIT Cancer Fighting Therapeutic
2024-02-13 11:45	UU:HOTH	News Release200	Hoth Therapeutics to Attend BIO CEO and Investor Conference, February 26-27, 2024
2024-01-18 08:20	UU:HOTH	News Release200	Hoth Therapeutics Announces it Received FDA Approval to Expand HT-001 Clinical Trial to Treat Severely Ill Patients
2023-12-27 08:21	UU:HOTH	News Release200	Hoth Therapeutics Announces Expansion of FDA Cleared First-In-Human Clinical Trial For Cancer Patients of HT-001 at University of Miami
2023-12-05 08:33	UU:HOTH	News Release200	Hoth Therapeutics Announces it Has Successfully Completed Manufacturing of its Cancer fighting HT-KIT for IND-Enabling Studies
2023-11-14 08:37	UU:HOTH	News Release200	Hoth Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Development of Hoth's Cancer Fighting HT-KIT
2023-11-10 08:00	UU:HOTH	News Release200	Hoth Therapeutics to Present at NobleCon's 19th Annual Emerging Growth Investor Conference, December 3-5, 2023
2023-10-05 10:03	UU:HOTH	News Release200	Hoth Therapeutics Announces Merveille.ai Artificial intelligence Initiative for Drug Discovery
2023-10-02 08:33	UU:HOTH	News Release200	FDA Grants Hoth Therapeutics Pre-IND Meeting for HT-KIT, Treatment for Cancer Patients
2023-09-15 14:38	UU:HOTH	News Release200	Hoth Therapeutics Announces Closing of $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
2023-09-13 13:43	UU:HOTH	News Release200	Hoth Therapeutics Announces $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
2023-09-13 08:16	UU:HOTH	News Release200	Hoth Therapeutics Announces Positive Results Killing Cancer Cells in Both Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia
2023-09-11 10:04	UU:HOTH	News Release200	Hoth Therapeutics Announces FDA Accepts Pre-Investigational New Drug (Pre-IND) Submission for HT-KIT, Treatment for Cancer Patients
2023-09-06 08:12	UU:HOTH	News Release200	Hoth Therapeutics Announces Positive Final Results from 14-day Phase 1b Clinical Trial of BioLexa
2023-08-09 08:13	UU:HOTH	News Release200	Hoth Therapeutics Announces Positive Preclinical End Point Results of HT-ALZ Treatment for Alzheimer's Disease
2023-07-25 08:12	UU:HOTH	News Release200	Hoth Therapeutics Announces Major Milestone of First Patient Dosed in Phase 2a Clinical Trial
2023-07-19 08:02	UU:HOTH	News Release200	Hoth Therapeutics Receives Protocol Approval for HT-001 Cancer Therapeutic
2023-06-14 08:12	UU:HOTH	News Release200	Hoth Therapeutics Announces IRB Approval for FDA Cleared First-In-Human Clinical Trial of HT-001 at Second Clinical Site
2023-06-06 08:02	UU:HOTH	News Release200	Hoth Therapeutics Announces Positive Preclinical Results of HT-ALZ treatment for Alzheimer's Disease
2023-05-12 08:38	UU:HOTH	News Release200	Hoth Therapeutics and Algorithm Sciences Terminate Letter of Intent to Merge